Evidence map›Paper›PMID 42807182›Full record

ArticleFrontiers in cellular and infection microbiology2026

Clinical gradient and predictors for stepwise resistance escalation of carbapenem-susceptible, carbapenem-resistant, and difficult-to-treat resistant

Lin Chen, Donghong Yin, Huimin Hu, Jianbang Kang, Renaguli Rouzimaimaiti, Jinju Duan, Ruigang Hou

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lin Chen *School of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi, China.
Donghong Yin *Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Huimin HuSchool of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi, China.
Jianbang KangDepartment of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Renaguli RouzimaimaitiSchool of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi, China.
Jinju DuanDepartment of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Ruigang HouDepartment of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Difficult-to-treat resistant Methods: A retrospective case-control study was conducted from January 2020 to December 2025 at a tertiary teaching hospital. Results: During the study period, 2,692 Conclusion: Antimicrobial resistance in

Indexed as

Anti-Bacterial AgentsCarbapenemsPseudomonas aeruginosaPseudomonas InfectionsCase-Control StudiesDrug Resistance, BacterialFemaleHumansMicrobial Sensitivity TestsMiddle AgedRetrospective StudiesRisk FactorsAnti-Bacterial AgentsCarbapenemsantimicrobial resistancedifficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA)resistance acquisitionresistance escalationrisk factors

Identifiers

PMID42807182
PMCPMC13616671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.